Welcome to our dedicated page for LMDX news (Ticker: LMDX), a resource for investors and traders seeking the latest updates and insights on LMDX stock.
LumiraDx Limited (Nasdaq: LMDX) delivers cutting-edge point-of-care diagnostic solutions through its portable testing platform. This page provides investors and healthcare professionals with essential updates on regulatory milestones, financial developments, and strategic partnerships shaping the company's trajectory in global diagnostics.
Key resources include press releases about FDA submissions, distribution agreements with European partners, and progress updates on Roche's acquisition of LumiraDx's platform business. Discover official announcements regarding new assay validations, financial results, and operational expansions across key markets.
Regular updates cover product innovations like the SARS-CoV-2 Ag Ultra test, partnership developments with healthcare distributors, and financial performance metrics. All content is verified through primary sources to ensure accuracy for investment research and industry analysis.
Bookmark this page for streamlined access to LumiraDx's latest corporate communications. Check back frequently to stay informed about developments impacting diagnostic accessibility and the company's position in rapid testing markets.
LumiraDx Limited (Nasdaq: LMDX) has received CE Mark for its Amira System, a next-generation COVID-19 antigen testing solution that combines high sensitivity with affordability. The system includes the Amira Analyzer and requires just 15 minutes to deliver results. Clinical data shows it has a positive agreement of 90.00% and negative agreement of 99.31% against RT-PCR. The Amira System will soon be available in Europe, featuring a starter kit with one analyzer and 200 test strips. The company plans to pursue further regulatory approvals for broader use.
LumiraDx Limited (Nasdaq: LMDX) announced receiving CE Mark certification for two new molecular tests: Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete. These tests enhance global testing capabilities with high sensitivity levels, indicated by positive percent agreements of 97.7% for SARS-CoV-2 and 94.1% for influenza A. The new assays utilize advanced qSTAR technology for quick results, available in 20 minutes. As the pandemic continues, LumiraDx aims to improve laboratory operations and address testing barriers.
LumiraDx Limited (Nasdaq: LMDX) has expanded its cardiovascular testing portfolio by receiving a CE Mark for its NT-proBNP test to assist in diagnosing congestive heart failure (CHF) and an updated CE Mark for its D-Dimer test, which now allows clinicians to rule out venous thromboembolism (VTE) in symptomatic patients. Both tests, designed for near-patient testing, provide rapid results—12 minutes for NT-proBNP and 6 minutes for D-Dimer—using a simple fingerstick sample. The D-Dimer test showcases a 99.5% negative predictive value when combined with a pre-test probability score.
LumiraDx Limited (Nasdaq: LMDX) announced that its HbA1c test has received CE Marking, enabling rapid monitoring for diabetes. The automated fingerstick assay, part of the LumiraDx Platform, delivers results in under seven minutes, addressing the increasing need for accessible HbA1c testing in community healthcare. With global diabetes-related healthcare expenditures soaring to USD 966 billion in 2021, this test aims to improve patient management and streamline testing processes for clinicians. The platform also includes tests for various conditions, ensuring comprehensive healthcare solutions.
LumiraDx Limited (Nasdaq: LMDX) announced on May 20, 2022, that its rapid COVID-19 antigen test received Emergency Use Listing (EUL) from the World Health Organization (WHO). This microfluidic immunofluorescence assay demonstrates 95% positive agreement with RT-PCR tests when used within 12 days of symptom onset. LumiraDx has distributed 5,000 testing platforms in Africa through a partnership with the Bill and Melinda Gates Foundation. The test aims to enhance pandemic management while the company continues to develop a pipeline of additional diagnostic tests.
LumiraDx (LMDX) announced its SARS-CoV-2 Ag Ultra Test received CE Marking, offering results in just 5 minutes. This test enhances clinical decision-making at the point of care, supporting treatment and infection control. The Ultra Test operates on the LumiraDx Platform, capable of processing up to 80 tests per day. It boasts a positive agreement of 92.7% and negative agreement of 100% with RT-PCR tests. The high sensitivity of 97.4% for potentially infectious individuals is crucial, especially given the higher asymptomatic carriage rates of the Omicron variant.
LumiraDx Limited (LMDX) reported strong growth in its Q1 2022 financial results, with revenues of $126.4 million, up from $106.9 million in Q1 2021. The company delivered over 4,000 instruments to customers, increasing its install base to 25,000. Notably, COVID-related products contributed $77.5 million to revenues. However, LumiraDx faced a net loss of $55.7 million and an adjusted operating loss of $22.9 million. The company maintains a strong cash position of $166 million and anticipates closing a financing agreement for an additional $50 million in Q2 to support growth.
LumiraDx Limited (Nasdaq: LMDX) has announced that it will release its first quarter financial results on May 11, 2022. The company will hold a conference call and webcast at 4:30 PM Eastern Time to discuss these results and highlight key business developments. Investors and analysts can access the call via a dedicated phone line or online, and a replay will be available on LumiraDx's investor website shortly after the call concludes. This session aims to provide insights into the company's performance in the first quarter of 2022.
LumiraDx Limited (Nasdaq:LMDX) reported strong financial results for the fourth quarter and full year ended December 31, 2021. Full year revenues surged to $421.4 million, up from $139.2 million in 2020. Fourth quarter revenues reached $118.3 million, marking a sequential increase from $109.1 million in Q3 2021. The company shipped over 21,000 instruments, contributing to the growth driven by demand for SARS-CoV-2 Antigen tests. However, LumiraDx reported a net loss of $100.8 million for 2021, with cash reserves of $132.1 million as of year-end.
LumiraDx (Nasdaq: LMDX) will release its fourth quarter and full year 2021 financial results on March 10, 2022. A conference call is scheduled for 8 AM Eastern Time that day to discuss the results and business highlights. The company, established in 2014, specializes in next-generation point-of-care diagnostics, offering over 30 tests for various health conditions. With more than 1600 employees globally, LumiraDx focuses on transforming healthcare delivery through innovative diagnostic solutions.
